# Nouscom

> Clinical-stage developer of neoantigen-targeted immunotherapies for cancer interception and treatment.

## Why it is interesting

Its Series D funds a registration-enabling development step, making trial execution and evidence quality central to the investment case.

## Profile

- **Latest funding:** Series D — $135M (EUR120M; company-disclosed equivalent) (October 19, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $135M
- **Stage:** growth
- **Status:** private
- **Industries:** healthtech
- **Coverage:** full
- **Last updated:** 2026-10-19
- **Latest funding investors:** M Ventures, Revelation Partners, Angelini Industries (through Angelini Investments), European Investment Bank (through Aurea), Neva SGR, 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (InnoBio2), CDP Venture Capital (Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures, XGEN Ventures

## Funding history

- Series D · $135M (EUR120M; company-disclosed equivalent) · October 19, 2026
  Source: https://nouscom.com/2026/10/19/nouscom-raises-e120-million-135-million-in-oversubscribed-series-d-financing-and-will-present-long-term-cancer-interception-clinical-data-in-lynch-syndrome-carriers-at-esmo/

## Investors in our directory

- https://venturecapitaltracker.com/fund/m-ventures
- https://venturecapitaltracker.com/fund/revelation-partners

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 19, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/nouscom